Packiaraj Jeyachandran Manohari, Venkateswaran Chidambaram Seshadri, Narendra Reddy Parvatha Janarthana Reddy, Sumathi Vinay Rao, Harshavardhana Reddy Venkatarangareddy, Janakiraman Kunchithapatham, Mahendhirababu Sankar, Guhan Himadeep Chowdary Eswara Rao, Srihariteja Seelamantula, Sathyanarayana Reddy Sanivarapu Venkata
Packiaraj Jeyachandran Manohari1*, Venkateswaran Chidambaram Seshadri1, Narendra Reddy Parvatha Janarthana Reddy1, Sumathi Vinay Rao1, Harshavardhana Reddy Venkatarangareddy1, Janakiraman Kunchithapatham2, Mahendhirababu Sankar1, Guhan Himadeep Chowdary Eswara Rao1, Srihariteja Seelamantula1, Sathyanarayana Reddy Sanivarapu Venkata1
1Hibrow Healthcare Pvt Ltd and Nutrimed Lifesciences Pvt Ltd, Survey No. 258, Thiruvandavar Village, Sirupinayur Taluk, Uthiramerur Panchayat, Kanchipuram District, Via Mamandoor - Uthiramerur Road,
Chengalpet – 603308, Chennai, Tamil Nadu, India.
2Professor and Head of the Department, Department of Pharmacy, Annamalai University, Annamalai Nagar - 608002, Tamil Nadu, India.
Volume - 15,
Issue - 9,
Year - 2022
In this research an attempt was made to develop and evaluate a commercially feasible and cost-effective tablet and oral suspension of Solifenacin Succinate. In international market, Solifenacin Succinate is available in both tablet and oral suspension dosage form. In Indian market, only tablet dosage form is available. Hence it was decided to make a formulation of Solifenacin Succinate that will not only be used as an oral solid dosage form in the form of tablet but also can be readily converted to oral suspension by extemporaneous means. A simple direct blending process was followed using limited excipients to make the end product cost-effective. The finalized product was comparable to the international brand product with respect to physico-chemical attributes, drug release and stability. The prepared tablet was made into an oral suspension using Ora-Plus® and Ora-Sweet® and the compounded suspension showed good palatability, organoleptics, chemical and microbial stability.
Cite this article:
Packiaraj Jeyachandran Manohari, Venkateswaran Chidambaram Seshadri, Narendra Reddy Parvatha Janarthana Reddy, Sumathi Vinay Rao, Harshavardhana Reddy Venkatarangareddy, Janakiraman Kunchithapatham, Mahendhirababu Sankar, Guhan Himadeep Chowdary Eswara Rao, Srihariteja Seelamantula, Sathyanarayana Reddy Sanivarapu Venkata. Development of commercially feasible and Cost-effective tablet of Solifenacin succinate that can be compounded into an oral suspension. Research Journal of Pharmacy and Technology. 2022; 15(9):4166-2. doi: 10.52711/0974-360X.2022.00699
Packiaraj Jeyachandran Manohari, Venkateswaran Chidambaram Seshadri, Narendra Reddy Parvatha Janarthana Reddy, Sumathi Vinay Rao, Harshavardhana Reddy Venkatarangareddy, Janakiraman Kunchithapatham, Mahendhirababu Sankar, Guhan Himadeep Chowdary Eswara Rao, Srihariteja Seelamantula, Sathyanarayana Reddy Sanivarapu Venkata. Development of commercially feasible and Cost-effective tablet of Solifenacin succinate that can be compounded into an oral suspension. Research Journal of Pharmacy and Technology. 2022; 15(9):4166-2. doi: 10.52711/0974-360X.2022.00699 Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-9-59
4. Uma Singh. et al Prevalence and risk factors of urinary incontinence in Indian women: A hospital-based survey. Indian Journal of Urology. 2013; 29(1): 31-36. DOI: 10.4103/0970-1591.109981.
5. Aathira KA. et al Prevalence and factors of urinary incontinence among postmenopausal women attending the obstetrics and gynecology outpatient service in a tertiary health care center in Kochi, Kerala. Indian Journal of Community Medicine. 2019; 44(5): 30-33. DOI: 10.4103/ijcm.IJCM_29_19.
8. Vishal Bansal. et al Tolerance of bladder antispasmodics in children with urinary incontinence: An observational study from North India. Indian Journal of Pharmacology. 2011; 43(6): 744-745. DOI: 10.4103/0253-7613.89847.
10. Kalyani P. et al Prevalence of urinary incontinence and its severity among women in urban Chidambaram – a cross sectional study. International Journal Of Community Medicine And Public Health. 2018;5(10):4543-47. DOI: http://dx.doi.org/10.18203/2394-6040.ijcmph20184007.
11. Bhanu Priya. et al Prevalence and risk factors of urinary incontinence among women delivering in a tertiary care center of northern india. Obstetrics & Gynecology International Journal. 2015;3(4):11-12. DOI: 10.15406/ogij.2015.03.00087.
12. Sanjay Sinha. et al The Urological Society of India survey on urinary incontinence practice patterns among urologists. Indian Journal of Urology. 2018;34(3):202-210. DOI: 10.4103/iju.IJU_85_18.
13. Bijit Biswas. et al Urinary incontinence, its risk factors, and quality of life: A study among women aged 50 years and above in a rural health facility of west bengal. Journal of Mid-life health. 2017;8(3):130-136. DOI: 10.4103/jmh.JMH_62_17.
14. Alyssa Greiman. et al Considerations in Pediatric Overactive Bladder. Textbook of Contemporary Pharmacotherapy of Overactive Bladder. 2019;231-244. DOI:10.1007/978-3-319-97265-7_14.
15. Malar Kodi Aathi. et al Understanding of Urodynamics Testing. Asian Journal of Nursing Education and Research. 2013;3(3):171-176.
16. Worlanso A. Shimray. et al Quality of life and health-seeking behavior of women with Postpartum urinary incontinence. Asian Journal of Nursing Education and Research.2020;10(3):298-304. DOI: 10.5958/2349-2996.2020.00062.2.
17. Christina Jose. et al Effectiveness of structured teaching programme on knowledge regarding pelvic floor muscle exercises in prevention of urinary incontinence among premenopausal women admitted in selected hospital Bangalore. Asian Journal of Nursing Education and Research. 2021; 11(3):307-310. DOI: 10.52711/2349-2996.2021.00074.
18. G. Jayathangaselvi. Assess the knowledge and attitude on urinary incontinence and demonstration of kegel exercise as primary prevention among women at rural community. International Journal of Nursing Education and Research. 2015;3(2):149-152.
19. R. Deepa. et al Save My Bladder. International Journal of Nursing Education and Research. 2020;8(4):483-487. Doi: 10.5958/2454-2660.2020.00106.4.
20. Yuvarani. G. et al Efficacy of Otago versus SAIL along with pelvic floor muscle strengthening exercise in avoiding urinary incontinence and fall risk among women. Research Journal of Pharmacy and Technology. 2019;12(3):1105-1110. Doi: 10.5958/0974-360X.2019.00181.1
21. Rajalaxmi. V. et al Efficacy of pelvic floor muscle training, yoga and cognitive behavioral therapy for urinary incontinence in diabetic women – a randomized controlled double binded study. Research Journal of Pharmacy and Technology. 2019; 12(10): 4618-4622. Doi: 10.5958/0974-360X.2019.00794.7
22. Pavithralochani V. et al Efficacy of kegel’s exercise vs pilates in subject with urinary incontinence during pregnancy. Research Journal of Pharmacy and Technology. 2019;12(12): 5943-5946. doi: 10.5958/0974-360X.2019.01031.X
23. Akio Sugihara. et al Composition of Solifenacin for use in solid formulation. US 2011/0065746A1. Patent published on 17th March 2011.
24. Ananda Kumar.CH. et al Development, formulation and evaluation of Solifenacin Succinate immediate release oral tablets by using starch and hpmc. International Journal of Research in Pharmaceutical and Nano sciences. 2013; 2(1): 91-100.
25. Suh Young Hee. et al Stable composition comprising Solifenacin. WO 2015/115750 A1. Patent published on 6th August 2015.
26. Naga Sudha. RKV. et al Design, Development and Evaluation of Solifenacin Succinate Tablets. Research Journal of Pharmaceutical Dosage Forms and Technology. 2015; 7(2): 111-117. doi: 10.5958/0975-4377.2015.00016.6
27. Hari Prasad Bhatta. et al Formulation and evaluation of Solifenacin Succinate immediate release tablets using various superdisintegrants. World Journal of Pharmacy and Pharmaceutical Sciences. 2016; 5(6): 768-781. DOI: 10.20959/wjpps20166-6633
28. Bhavana V. et al RP-HPLC method for estimation of Solifenacin Succinate in API and Tablet dosage form. Asian Journal of Pharmaceutical Analysis. 2019;9(3):118-122. DOI:10.5958/2231-5675.2019.00022.X
29. Rihana Parveen Shaik. et al Analytical method development and validation of Solifenacin in pharmaceutical dosage forms by RPLC. ISRN Analytical Chemistry. 2014;4(3):1-5. DOI: 10.1155/2014/132020
30. Lokesh Singh. et al Spectrophotometric estimation of Solifenacin Succinate in tablet formulations. Pharmaceutical Methods. 2011;2(1):21-24. Doi: 10.4103/2229-4708.81086.
31. Vijayasree V. et al Validated RP-HPLC Method For The Estimation of Solifenacin Succinate In Tablet Dosage Forms. Pharmanest. 2013; 4(2): 206-212.
32. Radhakrishna S. et al A validated rapid stability-indicating method for the determination of related substances in Solifenacin Succinate by ultra-fast liquid chromatography. Journal of Chromatographic Science. 2010;48(10):807-810. Doi: 10.1093/chromsci/48.10.807.
33. Shashikant B Landge. et al Development and validation of new chromatographic method for the determination of enatiomeric and diastereomeric purity of Solifenacin Succinate: An Antimuscarinic Agent. Chromatography Research International. 2011; 7(7): 7 pages. Doi:10.4061/2011/243491.
34. Nilesh Desai. et al Development and validation of stability indicating HPLC method for determination of Solifenacin in bulk formulations. 2011;3(1):70-74.
35. Divya Teja G. et al Quantitative analysis of Solifenacin Succinate in pharmaceutical dosage form using UV absorption spectroscopy. 2013;6(3):195-198.
36. RAKESH B. et al UV Spectrophotometric method development and validation for the quantitative estimation of Solifenacin Succinate in Tablets. International Journal of Pharmacy and Pharmaceutical Sciences. 2014;6(10):190-193.
37. Seetharaman R. et al Development and validation of first order derivative spectrophotometric method for estimation of Solifenacin Succinate in pharmaceutical formulation. International Journal of Research in Pharmaceutical and Biomedical Sciences. 2011; 2(3): 1052-1057.
38. Saroj Kumar R. et al A RP-HPLC method development and validation for the estimation of Solifenacin in bulk and pharmaceutical dosage forms. International Journal of Bioassays. 2012;01(12):210-213.
39. Mathrusri Annapurna M. et al A validated liquid chromatographic method for the determination of Solifenacin Succinate (Urinary Antispasmodic) in Tablets. Chemical Science Transactions. 2014;3(2):602-607.
40. Desai D. et al Development and validation of stability-indicating HPLC method for Solifenacin Succinate: Isolation and identification of major degradation product. Acta Chromatographica. 2012;24(3):399-418. DOI: https://doi.org/10.1556/achrom.24.2012.3.5.
41. Rami Reddy BV. et al Development and validation of specific stability indicating high performance liquid chromatographic methods for related compounds and assay of Solifenacin Succinate. Journal of Chemistry. 2013;1-10. DOI: https://doi.org/10.1155/2013/412353.
42. Madhu Kiran M. et al Two direct simple visible spectrophotometric assay methods of Solifenacin Succinate in oral tablet formulations. Resayan Journal of Chemistry. 2017;10(4): 1068-1074.
43. General chapters in USP Pharmacopoeia related to Disintegration, Friability, Repose Angle, Compressibility Index, Hausner Ratio etc.